None
Conditions
Interventions
Low-molecular-weight heparin (LMWH) group:Anticoagulation Protocol with Low-Molecular-Weight Heparin Sodium (LMWH) in DFPP:
Initial dose: 2000 IU intravenous bolus
Maintenance infusion: 200-500 U/hou
Nafamostat Mesilate Group:Anticoagulation Protocol with Nafamostat Mesilate in DFPP:
Initial bolus dose: 40 mg intravenous
Continuous infusion rate: 30–50 mg/hour
Dose adjustment: Dynamically titrate
Combined LMWH and Nafamostat Mesilate Group:Anticoagulation Protocol with Combined LMWH and Nafamostat Mesilate in DFPP:
Low-Molecular-Weight Heparin Sodium (LMWH):
Initial bolus: 2000 IU intravenous
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to <70 years, regardless of gender; 2.Meet the indications for DFPP therapy; 3.Voluntarily participates in this clinical trial and provides signed informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with psychiatric disorders or other conditions unable to cooperate with the treatment; 2.Patients requiring other anticoagulants for therapeutic reasons; 3.Individuals with a history of allergies or known hypersensitivity to the investigational drugs (nafamostat mesilate, citrate) or their excipients; 4.Pregnant women, women planning pregnancy in the near future, or lactating women; 5.Participation in another clinical trial within the past month; 6.Other conditions deemed ineligible by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Extracorporeal Circuit Coagulation Incidence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment Completion Rate;Extracorporeal Circuit Pressure During DFPP;Changes in Coagulation Function Before and After Treatment;4-Week Survival Rate; | — |
Countries
China
Contacts
Public ContactWang Fang
West China Hospital of Sichuan University
Outcome results
None listed